Charles Patrick G P, Ward Peter B, Johnson Paul D R, Howden Benjamin P, Grayson M Lindsay
Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia.
Clin Infect Dis. 2004 Feb 1;38(3):448-51. doi: 10.1086/381093. Epub 2004 Jan 12.
We assessed all episodes of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia at our hospital during a 12-month period (n=53) and compared those due to heterogeneous vancomycin-intermediate S. aureus (hVISA; n = 5, 9.4%) with those due to vancomycin-susceptible MRSA (n=48). Patients with hVISA bacteremia were more likely to have high bacterial load infections (P=.001), vancomycin treatment failure (persistent fever and bacteremia for >7 days after the start of therapy; P<.001), and initially low serum vancomycin levels (P=.006). These clinical markers of hVISA bacteremia may help focus diagnostic efforts and treatment.
我们评估了我院在12个月期间所有耐甲氧西林金黄色葡萄球菌（MRSA）菌血症病例（n = 53），并将异质性万古霉素中介金黄色葡萄球菌（hVISA；n = 5，9.4%）所致菌血症与万古霉素敏感MRSA所致菌血症（n = 48）进行了比较。hVISA菌血症患者更易发生高细菌载量感染（P = 0.001）、万古霉素治疗失败（治疗开始后持续发热和菌血症超过7天；P < 0.001）以及初始血清万古霉素水平较低（P = 0.006）。这些hVISA菌血症的临床标志物可能有助于集中诊断工作和治疗。
